Viridian Therapeutics, Inc.
TSHR program
thyroid eye disease (TED) and Graves’ disease
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for TSHR program (thyroid eye disease (TED) and Graves’ disease) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 16h ago
“Viridian plans to submit an Investigational New Drug (IND) application in Q4 2026”